---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-064749"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2026-10-05T11:32:18+00:00"
generated_at: "2026-10-12T14:44:15.178537+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Harrow closes $30M cash acquisition of TYRVAYA from Viatris, up to $70M in sales milestones

## Summary
- Paid Viatris $30.0M cash at closing, funded with cash on hand; up to $70M in contingent milestones tied to TYRVAYA net sales through Dec 31, 2029; total potential consideration $100M.
- Harrow acquired worldwide TYRVAYA rights except Japan; Viatris kept Japan commercialization rights and will pay Harrow tiered royalties on Japanese net sales.
- TYRVAYA is the first and only FDA-approved nasal spray for dry eye disease; approved in U.S., China and Taiwan, with marketing applications pending in additional markets.
- About 40 experienced Viatris personnel with TYRVAYA and dry eye knowledge are expected to join Harrow's Ocular Surface commercial team in Q4 2026.
- Harrow expects TYRVAYA to contribute more than $30 million in revenue in 2027; product complements VEVYE in the dry eye franchise and both use PhilRx pharmacy.

## SEC filing metadata
- accession: 0001628280-26-064749
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2026-10-05T11:32:18+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000162828026064749/0001628280-26-064749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000162828026064749/hrow-20261001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-064749
- JSON: https://secwatch.observer/filing/0001628280-26-064749.json
- Plain text: https://secwatch.observer/filing/0001628280-26-064749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.